Leerink Partnrs Weighs in on 908 Devices Inc.’s Q1 2025 Earnings (NASDAQ:MASS)

908 Devices Inc. (NASDAQ:MASS) – Leerink Partnrs issued their Q1 2025 earnings estimates for 908 Devices in a research report issued to clients and investors on Tuesday, April 30th. Leerink Partnrs analyst P. Souda expects that the company will earn ($0.31) per share for the quarter. The consensus estimate for 908 Devices’ current full-year earnings is ($1.27) per share. Leerink Partnrs also issued estimates for 908 Devices’ Q2 2025 earnings at ($0.28) EPS, Q3 2025 earnings at ($0.19) EPS and Q4 2025 earnings at ($0.16) EPS.

908 Devices Trading Down 0.4 %

NASDAQ MASS opened at $5.68 on Thursday. 908 Devices has a 52 week low of $4.85 and a 52 week high of $12.51. The stock has a market cap of $187.33 million, a price-to-earnings ratio of -5.31 and a beta of 1.02. The company has a 50-day moving average price of $6.59 and a two-hundred day moving average price of $7.08.

908 Devices (NASDAQ:MASS) last posted its earnings results on Tuesday, April 30th. The company reported ($0.33) EPS for the quarter, topping the consensus estimate of ($0.36) by $0.03. 908 Devices had a negative net margin of 68.57% and a negative return on equity of 20.47%. The firm had revenue of $9.99 million during the quarter, compared to analysts’ expectations of $9.29 million. During the same quarter in the prior year, the firm earned ($0.39) EPS. 908 Devices’s quarterly revenue was up 5.3% on a year-over-year basis.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. ARK Investment Management LLC grew its position in 908 Devices by 8.3% in the 4th quarter. ARK Investment Management LLC now owns 4,346,579 shares of the company’s stock worth $48,769,000 after purchasing an additional 333,119 shares during the last quarter. Granahan Investment Management LLC grew its position in 908 Devices by 10.6% in the 4th quarter. Granahan Investment Management LLC now owns 2,038,658 shares of the company’s stock worth $22,874,000 after purchasing an additional 195,368 shares during the last quarter. Iron Triangle Partners LP boosted its holdings in shares of 908 Devices by 31.1% in the fourth quarter. Iron Triangle Partners LP now owns 1,284,947 shares of the company’s stock valued at $14,417,000 after acquiring an additional 304,484 shares in the last quarter. Sumitomo Mitsui Trust Holdings Inc. boosted its holdings in shares of 908 Devices by 3.0% in the third quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 629,994 shares of the company’s stock valued at $4,196,000 after acquiring an additional 18,492 shares in the last quarter. Finally, AWM Investment Company Inc. acquired a new position in shares of 908 Devices during the third quarter valued at approximately $3,740,000. Institutional investors own 88.06% of the company’s stock.

908 Devices Company Profile

908 Devices Inc, a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling.